Daily home BNP monitoring in heart failure for prediction of impending clinical deterioration: results from the HOME HF study

McDonald, Kenneth; Troughton, Richard W.; Dahlström, Ulf; Dargie, Henry J.; Krum, Henry; Meer, Peter van der; McDonagh, Theresa A.; Atherton, J.; Kupfer, Ken; George, Richard C. San; Richards, Mark; Doughty, Robert N.

doi:10.1002/ejhf.1053

Cited by 21 publications

(33 citation statements)

References 22 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Main results of two trials are shown: the Double‐blind, RandOmised, two‐arm Parallel group, serum c‐terminal Propeptide of Procollagen type I (DROP‐PIP) trial and the Heart Failure Outpatient Monitoring Evaluation (HOME HF) study …”

Section: Main Results Of Clinical Trialsmentioning

confidence: 99%

“…HOME HF was designed as a randomized clinical trial to test the hypothesis that daily brain natriuretic peptide (BNP) measurements at home could improve outcomes, compared to a home management system without BNP measurements or routine clinical care, in patients with HF and reduced ejection fraction (HFrEF) . The study was terminated early because of slow enrolment and the need for an algorithm testing serial BNP changes.…”

Section: Main Results Of Clinical Trialsmentioning

confidence: 99%

“…The study was terminated early because of slow enrolment and the need for an algorithm testing serial BNP changes. Changes in BNP values, calculated using a moving average filter to reduce day‐to‐day fluctuations, were independently related to cardiac events and prediction was improved by adjustment for baseline values …”

Section: Main Results Of Clinical Trialsmentioning

confidence: 99%

See 2 more Smart Citations

March 2018 at a glance: clinical trials, co‐morbidities and treatment of mitral regurgitation

Metra

2018

European J of Heart Fail

View full text Add to dashboard Cite

Section: Main Results Of Clinical Trialsmentioning

confidence: 99%

Section: Main Results Of Clinical Trialsmentioning

confidence: 99%

Section: Main Results Of Clinical Trialsmentioning

confidence: 99%

See 1 more Smart Citation

March 2018 at a glance: clinical trials, co‐morbidities and treatment of mitral regurgitation

Metra

2018

European J of Heart Fail

View full text Add to dashboard Cite

“…102 Neutral results may be caused by both the type of the intervention and patients selection. 104 Telemedical Interventional Management in HF II (TIM-HF2) was a randomized, controlled trial investigating the impact of telemedicine on unplanned cardiovascular hospitalizations and mortality in HF patients. 103 Nurse home visits had also the greatest pooled cost savings.…”

Section: Telemedicinementioning

confidence: 99%

“…Although the trial showed the feasibility of this approach, it was terminated early because of slow enrolment, low event rates, and the need of an algorithm taking care of spontaneous BNP fluctuations. 104 Telemedical Interventional Management in HF II (TIM-HF2) was a randomized, controlled trial investigating the impact of telemedicine on unplanned cardiovascular hospitalizations and mortality in HF patients. Study patients were selected based on the analysis of the previous TIM-HF trial, which was neutral.…”

Section: Telemedicinementioning

confidence: 99%

Highlights in heart failure

et al. 2019

View full text Add to dashboard Cite

Heart failure (HF) remains a major cause of mortality, morbidity, and poor quality of life. It is an area of active research. This article is aimed to give an update on recent advances in all aspects of this syndrome. Major changes occurred in drug treatment of HF with reduced ejection fraction (HFrEF). Sacubitril/valsartan is indicated as a substitute to ACEi/ARBs after PARADIGM-HF (hazard ratio [HR], 0.80; 95% confidence interval [CI], 0.73 to 0.87 for sacubitril/valsartan vs. enalapril for the primary endpoint and Wei, Lin and Weissfeld HR 0.79, 95% CI 0.71-0.89 for recurrent events). Its initiation was then shown as safe and potentially useful in studies in patients hospitalized for acute HF. More recently, DAPA-HF trial showed the beneficial effects of the sodium-glucose transporter type 2 (SGLT2) inhibitor dapaglifozin vs. placebo, added to optimal standard therapy [HR, 0.74; 95% CI, 0.65 to 0.85;0.74; 95% CI, 0.65 to 0.85 for the primary endpoint]. Trials with other SGLT 2 inhibitors and in other patients, such as those with HF with preserved ejection fraction (HFpEF) or with recent decompensation, are ongoing. Multiple studies showed the unfavourable prognostic significance of abnormalities in serum potassium levels. Potassium lowering agents may allow initiation and titration of mineralocorticoid antagonists in a larger proportion of patients. Meta-analyses suggest better outcomes with ferric carboxymaltose in patients with iron deficiency. Drugs effective in HFrEF may be useful also in HF with mid-range ejection fraction. Better diagnosis and phenotype characterization seem warranted in HF with preserved ejection fraction. These and other burning aspects of HFpEF research are summarized and reviewed in this article.A multiparametric approach is often proposed for risk stratification of HF patients. The prognostic accuracy of the metabolic exercise test data combined with cardiac and kidney indexes risk score was found as superior to the HF Survival Score and Seattle HF model risk scores in a cohort of 6112 1106 D. Tomasoni et al.

show abstract

Minimally Invasive and Non‐Invasive Sensor Technologies for Predicting Heart Failure

Salman¹,

Al‐Ruweidi²,

Ouakad³

et al. 2022

Predicting Heart Failure

View full text Add to dashboard Cite

Daily home BNP monitoring in heart failure for prediction of impending clinical deterioration: results from the HOME HF study

Abstract: The HOME HF study demonstrates the feasibility of home BNP measurement and shows the potential value of fBNP as an index of emerging clinical deterioration. Assessment of the clinical value of this is required.

Cited by 21 publications

References 22 publications

March 2018 at a glance: clinical trials, co‐morbidities and treatment of mitral regurgitation

March 2018 at a glance: clinical trials, co‐morbidities and treatment of mitral regurgitation

Highlights in heart failure

Minimally Invasive and Non‐Invasive Sensor Technologies for Predicting Heart Failure

Contact Info

Product

Resources

About